Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.89 +0.01 (+0.09%)
At close: Oct 1, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMAA) Other Non-Current Liabilities (2025 - 2026)

Updated

Drugs Made In America Acquisition (DMAA) recorded Other Non-Current Liabilities of $6.19 million in Q2 2026.

Analysis

Drugs Made In America Acquisition (DMAA) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends

At the end of FY2025, Drugs Made In America Acquisition reported Other Non-Current Liabilities of $6.9 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 BlackRock 164.13 Bn 110.49 Bn -
2 Spdr Gold Trust 133.82 Bn -424.18 Bn -
3 Blackstone 84.08 Bn 79.01 Bn -
4 Brookfield 82.97 Bn -82.41 Bn 4.47 Bn
5 Kkr 81.05 Bn 47.53 Bn -
6 Brookfield Asset Management 71.64 Bn 67.88 Bn -
7 Apollo Global Management 65.67 Bn 3.35 Bn 10.56 Bn
8 Wheaton Precious Metals 61.89 Bn 57.32 Bn 687.86 Mn
9 Franco Nevada 46.13 Bn 43.49 Bn 451.00 Mn
10 Drugs Made In America Acquisition 335.55 Mn 335.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.19 Mn
Dec 31, 2025 6.90 Mn
Sep 30, 2025 6.90 Mn
API Access

Drugs Made In America Acquisition Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=DMAA&period=max&api_key=YOUR_API_KEY